TOL 3
Alternative Names: TOL-3Latest Information Update: 28 Mar 2024
At a glance
- Originator Toleranzia
- Class Anti-inflammatories; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anti-neutrophil cytoplasmic antibody-associated vasculitis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Anti-neutrophil-cytoplasmic-antibody-associated-vasculitis in Sweden
- 28 Feb 2020 Early research in Anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden (unspecified route)